Published in Drug Week, September 5th, 2003
This clinical trial, referred to as CART-2, will evaluate the drug's effect on atherosclerosis as reflected by the change in plaque volume in coronary arteries.
"This clinical trial will supply us with important anatomical data on the potential of AGI-1067 to reduce plaque in coronary blood vessels," said Russell M. Medford, MD, PhD, president and CEO for AtheroGenics. "If successful, this may provide us with enhanced label...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.